Formulation optimization of paclitaxel carried by PEGylated emulsions based on artificial neural network

被引:17
作者
Fan, TY
Takayama, K
Hattori, Y
Maitani, Y
机构
[1] Hoshi Univ, Inst Med Chem, Tokyo 142, Japan
[2] Hoshi Univ, Dept Pharmaceut, Tokyo 142, Japan
[3] Peking Univ, Sch Pharmaceut Sci, Dept Pharmaceut, Beijing 100083, Peoples R China
关键词
artificial neural network; emulsions; optimization; paclitaxel; PEGylated;
D O I
10.1023/B:PHAM.0000041467.28884.16
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To develop paclitaxel carried by injectable PEGylated emulsions, an artificial neural network (ANN) was used to optimize the formulation-which has a small particle size, high entrapment efficiency, and good stability-and to investigate the role of each ingredient in the emulsion. Methods. Paclitaxel emulsions were prepared by a modified ethanol injection method. A computer optimization technique based on a spherical experimental design for three-level, three factors [ soybean oil (X1), PEG-DSPE (X2) and polysorbate 80 (X3)] were used to optimize the formulation. The entrapment efficiency of paclitaxel (Y1) was quantified by HPLC; the particle size of the emulsions (Y2) was measured by dynamic laser light scattering and the stability of paclitaxel emulsions was monitored by the changes in drug concentration (Y3) and particle size (Y4) after storage at 4degreesC. Results. The entrapment efficiency, particle size and stability of paclitaxel emulsions were influenced by PEG-DSPE, polysorbate 80, and soybean oil. Paclitaxel emulsions of small size (262 nm), high entrapment efficiency (96.7%), and good stability were obtained by the optimization. Conclusions. A novel formulation for paclitaxel emulsions was optimized with ANN and prepared. The contribution indices of each component suggested that PEG-DSPE mainly contributes to the entrapment efficiency and particle size of paclitaxel emulsions, while polysorbate 80 contributes to stability.
引用
收藏
页码:1692 / 1697
页数:6
相关论文
共 30 条
[1]   ARTIFICIAL NEURAL NETWORKS - IMPLICATIONS FOR PHARMACEUTICAL SCIENCES [J].
ACHANTA, AS ;
KOWALSKI, JG ;
RHODES, CT .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1995, 21 (01) :119-155
[2]   Preparation, characterization, molecular modeling and in vitro activity of paclitaxel-cyclodextrin complexes [J].
Alcaro, S ;
Ventura, CA ;
Paolino, D ;
Battaglia, D ;
Ortuso, F ;
Cattel, L ;
Puglisi, G ;
Fresta, M .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (12) :1637-1641
[3]   SINGLE BILAYER LIPOSOMES PREPARED WITHOUT SONICATION [J].
BATZRI, S ;
KORN, ED .
BIOCHIMICA ET BIOPHYSICA ACTA, 1973, 298 (04) :1015-1019
[4]   Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel [J].
Constantinides, PP ;
Lambert, KJ ;
Tustian, AK ;
Schneider, B ;
Lalji, S ;
Ma, WW ;
Wentzel, B ;
Kessler, D ;
Worah, D ;
Quay, SC .
PHARMACEUTICAL RESEARCH, 2000, 17 (02) :175-182
[5]   Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes [J].
Crosasso, P ;
Ceruti, M ;
Brusa, P ;
Arpicco, S ;
Dosio, F ;
Cattel, L .
JOURNAL OF CONTROLLED RELEASE, 2000, 63 (1-2) :19-30
[6]   Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics [J].
Dosio, F ;
Arpicco, S ;
Brusa, P ;
Stella, B ;
Cattel, L .
JOURNAL OF CONTROLLED RELEASE, 2001, 76 (1-2) :107-117
[7]  
HASSIAN AS, 1991, PHARM RES, V8, P1248
[8]   FEASIBILITY OF DEVELOPING A NEURAL NETWORK FOR PREDICTION OF HUMAN PHARMACOKINETIC PARAMETERS FROM ANIMAL DATA [J].
HUSSAIN, AS ;
JOHNSON, RD ;
VACHHARAJANI, NN ;
RITSCHEL, WA .
PHARMACEUTICAL RESEARCH, 1993, 10 (03) :466-469
[9]   Development of nonionic sulfactant/phospholipid o/w emulsion as a paclitaxel delivery system [J].
Kan, P ;
Chen, ZB ;
Lee, CJ ;
Chu, IM .
JOURNAL OF CONTROLLED RELEASE, 1999, 58 (03) :271-278
[10]   Monte Carlo docking simulations of cyclomaltoheptaose and dimethyl cyclomaltoheptaose with paclitaxel [J].
Kim, H ;
Choi, J ;
Kim, HW ;
Jung, SH .
CARBOHYDRATE RESEARCH, 2002, 337 (06) :549-555